J9041 Injection, bortezomib, 0.1mg
Also known as: bortezomib, Velcade
Intravenous injection of bortezomib, a proteasome inhibitor chemotherapy agent, dosed per 0.1 milligram.
In Plain Language
protein-blocking cancer drug; cellular cleanup inhibitor
Clinical Context
First-line therapy for multiple myeloma and mantle cell lymphoma. Inhibits proteasome function, inducing cell cycle arrest and apoptosis.
RVU Information
CPT J9041 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J9041?
CPT J9041 (Injection, bortezomib, 0.1mg) is a J Codes (Drugs) code. Intravenous injection of bortezomib, a proteasome inhibitor chemotherapy agent, dosed per 0.1 milligram.
How is J9041 administered?
CPT J9041 is administered by a healthcare provider, typically via injection or infusion. First-line therapy for multiple myeloma and mantle cell lymphoma. Inhibits proteasome function, inducing cell cycle arrest and apoptosis. It is used by Hematology/Oncology, Medical Oncology.
When is CPT J9041 used?
First-line therapy for multiple myeloma and mantle cell lymphoma. Inhibits proteasome function, inducing cell cycle arrest and apoptosis.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.